Cargando…
Improving chemotherapeutic efficiency in acute myeloid leukemia treatments by chemically synthesized peptide interfering with CXCR4/CXCL12 axis
Bone marrow stroma can protect acute myeloid leukemia (AML) cells against chemotherapeutic agents and provide anti-apoptosis and chemoresistance signals through secreting chemokine CXCL12 to activate its receptor CXCR4 on AML cells, resulting in minimal residual leukemia and relapse. Therefore disru...
Autores principales: | Li, Xiaojin, Guo, Hua, Duan, Hongyang, Yang, Yanlian, Meng, Jie, Liu, Jian, Wang, Chen, Xu, Haiyan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4633653/ https://www.ncbi.nlm.nih.gov/pubmed/26538086 http://dx.doi.org/10.1038/srep16228 |
Ejemplares similares
-
Targeting the CXCR4/CXCL12 axis with the peptide antagonist E5 to inhibit breast tumor progression
por: Guo, Hua, et al.
Publicado: (2017) -
A designed peptide targeting CXCR4 displays anti-acute myelocytic leukemia activity in vitro and in vivo
por: Li, Xiaojin, et al.
Publicado: (2014) -
Targeting the CXCL12/CXCR4 axis in acute myeloid leukemia: from bench to bedside
por: Cho, Byung-Sik, et al.
Publicado: (2017) -
Significance of CXCL12/CXCR4 Ligand/Receptor Axis in Various Aspects of Acute Myeloid Leukemia
por: Yazdani, Zinat, et al.
Publicado: (2020) -
Anti-tumor activity of nanomicelles encapsulating CXCR4 peptide antagonist E5
por: Fang, Xiaocui, et al.
Publicado: (2017)